Prasugrel - the saga continues. Gets approval to launch in the EU; positive study results versus Plavix for a certain group of patients; but controversy swirls around FDA approval process. Synta's …
Today’s Top Three in Pharma 021809
Ahhh, the politics of drug approval processes. Some sniping going on about who was and wasn't included in the FDA review panel for prasugrel. No matter what choices you make, somebody's going to paint …
Today’s Top Three in Pharma 020409
Finally! New anti-clotting drug prasugrel (Effient) is given a thumbs up by advisory committee! Great news for Daiichi Sankyo and Eli Lilly. King Pharmaceuticals the latest to announce major layoffs …
Today’s Top Three in Pharma 020209
The FDA gives a hint of hope for the long-delayed Eli Lilly/Daiichi Sankyo drug prasugrel. Burrow deep inside this 357-page FDA document just posted online, and you’ll find this jargony but …
Pharma News 10_20
Novartis to cut a bunch more (sales) jobs; does another management shuffle - As reorganizations go, this one reaches most parts of the company. First, the drugmaker is cutting 550 sales reps, although …
Pharma News 10_03
Is Eli Lilly the "mystery suitor" for ImClone? - Eli Lilly & Co. is in advanced talks to buy cancer-drug developer ImClone Systems for $70 a share, or $6.1 billion, The Wall Street Journal …